Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs

被引:64
作者
Ananworanich, J
Moor, Z
Siangphoe, U
Chan, J
Cardiello, P
Duncombe, C
Phanuphak, P
Ruxrungtham, K
Lange, J
Cooper, DA
机构
[1] HIV NAT, Thai Red Cross AIDS Res Ctr, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Bangkok, Thailand
[3] Int AIDS Therapy Evaluat Ctr, Amsterdam, Netherlands
[4] Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[5] Univ New S Wales, Sydney, NSW, Australia
关键词
rash; non-nucleoside reverse transcriptase inhibitor; efavirenz; nevirapine; risk factors; incidence; antiretrovirals;
D O I
10.1097/00002030-200501280-00011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the incidence and risk factors for rash in Thai patients taking four different non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. Methods: HIV-positive, anti retroviral-naive patients enrolled in the 2NN study in Thailand and followed for at least 1 week were included. Patients were randomized to efavirenz (EFV) 600 mg once daily (OD) versus nevirapine (NVP) 200 mg twice daily (BD) versus NVP 400 mg OD versus NVP 400 mg OD + EFV 800 mg OD with stavudine/lamivudine. Results: Of 202 patients, 95 (47%) and 69 (34.2%) developed a rash from all reasons and from NNRTI, respectively. For NNRTI-related rash the incidences were EFV (20%), NVP BD (21%), NVP OD (38%) and NVP + EFV (67%). The proportions of patients with grade 1, 11 and III within the four treatment arms are as follows: EFV, 4.3, 13 and 2.9%; NVP BD, 2.3, 15.9 and 2.3%; NVP OD, 12.8, 19.1 and 6.41Y.; and NVP + EFV, 11.9, 47.6 and 7.1%. Multivariate analyses showed females with CD4 cell count >= 250 x 10(6) cells/l, high body mass index >= 21.3 kg/m(2)), and a rise in CD4 (>= 53 x 10(6) cells/l) and alanine aminotransferase (ALT) (>= 34 U/l) at week 4 to be risk factors for rash. Conclusions: Thai patients had a high incidence of NNRTI-related rash when treated with NVP + EFV or NVP OD. NVP if used BD had the same rash incidence as EFV for rash of all grades. Females, and persons with earlier HIV disease or with a large rise in CD4+ cell count after starting therapy are at greater risk for NNRTI-related rash (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 26 条
[1]  
Ananworanich J., 2003, Journal of Infectious Diseases and Antimicrobial Agents, V20, P109
[2]   Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy [J].
Antinori, A ;
Baldini, F ;
Girardi, E ;
Cingolani, A ;
Zaccarelli, M ;
Di Giambenedetto, S ;
Barracchini, A ;
De Longis, P ;
Murri, R ;
Tozzi, V ;
Ammassari, A ;
Rizzo, MG ;
Ippolito, G ;
De Luca, A .
AIDS, 2001, 15 (12) :1579-1581
[3]   Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily [J].
Autar, RS ;
Ananworanich, J ;
Apateerapong, W ;
Sankote, J ;
Hill, A ;
Hirschel, B ;
Cooper, D ;
Lange, J ;
Phanuphak, P ;
Ruxrungtham, K ;
Burger, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (04) :785-790
[4]   Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids [J].
Barreiro, P ;
Soriano, V ;
Casas, E ;
Estrada, V ;
Téllez, MJ ;
Hoetelmans, R ;
de Requena, DG ;
Jiménez-Nácher, I ;
González-Lahoz, J .
AIDS, 2000, 14 (14) :2153-2157
[5]   Sex differences in nevirapine rash [J].
Bersoff-Matcha, SJ ;
Miller, WC ;
Aberg, JA ;
van der Horst, C ;
Hamrick, HJ ;
Powderly, WG ;
Mundy, LM .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (01) :124-129
[6]  
*BOEHR ING PHARM I, 2004, VIR PACK INS
[7]  
Boffito M, 2004, ANTIVIR THER, V9, P423
[8]  
*BRIST MY SQUIBB C, 2003, SUST PACK INS
[9]   Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430
[10]   Toxic epidermal necrolysis induced by nevirapine therapy: Description of two cases and review of the literature [J].
Cattelan, AM ;
Trevenzoli, M ;
Sasset, L ;
Sgarabotto, D ;
Lanzafame, M ;
Meneghetti, F .
JOURNAL OF INFECTION, 2001, 43 (04) :246-249